Summary
Thirteen patients in complete remission from acute nonlymphoblastic leukaemia or in chronic phase of chronic myelocytic leukaemia were treated with total body irradiation, cyclophosphamide and allogeneic bone marrow transplantation (BMT). Ciclosporin (CS) was administered for the prevention and the treatment of Graft versus Host Disease. Blood concentrations of CS were determined by Radioimmunoassay (RIA) and by High Performance Liquid Chromatography (HPLC). Trough levels of CS in peripheral blood as measured by RIA exceeded HPLC derived levels in nearly all (56/58) samples with a ratio of RIA: HPLC ranging from 2.43±1.42 at day 12 to 3.65±1.86 at day 26 after BMT (\(\bar x\)±SD). A comparable ratio was found as regards the peak concentrations of CS in peripheral blood. Neither the dose of CS (0.5–3.0 mg/kg/day intravenously; 3.0–5.0 mg/kg/day per os) nor the duration of treatment (12, 19, 26 or 33 days after start of CS) were a significant factor as regards the ratio between HPLC and RIA. Concentrations of CS were also determined in bone marrow nucleated cells at 1 hour after the drug infusion had started. Here the ratio of RIA versus HPLC varied upon the duration of CS treatment with a highest ratio of 8.75±8.74 at day 12 after BMT. Bone marrow levels corresponded well with blood trough concentrations (p<0.01). It is concluded that the concentrations of CS in blood and bone marrow as determined by RIA and HPLC differ significantly, though consistently. At present, no advantage can be attributed to either method of analysis for routine clinical monitoring, as long as detailed information on the immunosuppressive and the toxic characteristics of CS metabolites in humans is lacking.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atkinson K, Boland J, Britton K, Biggs JC (1983) Blood and tissue distribution of cyclosporine in humans and mice. Transpl Proc 15: 2430–2433
Burckart GJ, Starzl TE, Venkataramanan R, Hashim H, Wang L, Wang P, Makowka L, Zeevi A, Ptachcinski RJ, Knapp JE, Iwatsuki S, Esquivel C, Sanghvi A, van Thiel DH (1986) Excretion of cyclosporine and its metabolites in human bile. Transpl Proc 18 (Suppl): 46–49
Burckart G, Starzl T, Williams L, Sanghvi A, Gartner C, Venkataramanan R, Zitelli B, Malatack J, Urbach A, Diven W, Ptachcinski R, Shaw B, Iwatsuki S (1985) Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transpl Proc 17: 1172–1175
Garruthers SG, Freeman DJ, Koegler JC, Howson W, Keown PA, Laupacis A, Stiller CR (1983) Simplified liquid chromatographic analysis for cyclosporin A and comparison with radioimmunoassay. Clin Chem 29: 180–183
Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Stran TB (1984) Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann Intern Med 101: 667–682
Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M, Appelbaum FR, Bensinger WF, Buckner CD, Clift RA, Doney K, Fefer A, McGriffin R, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP (1985) Cyclosporine as prophylaxis for graft versus host disease: A randomized study in patients undergoing marrow transplantation for acute non-lymphoblastic leukaemia. Blood 65: 1325–1334
Donatsch P, Abisch E, Honberger M, Traber R, Trapp M, Voges R (1981) A radioimmunoassay to measure Cyclosporin A in plasma and serum samples. J Immunoassay 2 (1): 19–24
Editorial (1985) Cyclosporin in Autoimmune Disease. Lancet i: 909–911
Gale RP, Kay HEM, Rimm AA, Bortin MM (1982) Bone marrow transplantation for acute leukaemia in first remission. Lancet ii: 1006–1009
Gluckman E, Devergie A, Poirier O, Lokiec F (1983) Use of cyclosporine as prophylaxis of graft-versus-host-disease after human allogeneic bone marrow transplantation: report of 38 patients. Transpl Proc 15: 2628–2633
Holt DW, Marsden JT, Johnston A (1986) Measurement of cyclosporine: Methodological problems. Transpl Proc 18 (Suppl): 101–110
Kahan BD, Van Buren CT, Boileau M, Ried M, Payne WD (1983) Cyclosporin A tissue levels in a cadaveric renal allograft recipient. Transplantation 35: 96–99
Keown PA, Stiller CR, Ulan RA, Sinclair NR, Wall WJ, Garruthers G, Howson W (1981) Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet i: 686–689
Keown PA, Stiller CR, Stawecki M, Freeman D (1986) Pharmacokinetics of cyclosporine in solid organ transplantation. Transpl Proc 18 (Suppl): 160–164
Lensmeyer GL, Fields BL (1985) Improved liquid-chromatographic determination of cyclosporine, with concomitant detection of a cell bound metabolite. Clin Chem 31: 196–201
Thomas ED, Storb R, Clift RA (1975) Bone marrow transplantation. N Engl J Med 292: 832–895
Varghese Z, Chan MK, Steele LV, Sweny P, Fernando ON, Moorhead JF (1984) How to measure cyclosporin. Lancet (letter): 1407
Venkataramanan R, Starzl TE, Yang S, Burckart GJ, Ptachcinski RJ, Shaw BW, Iwatsuki S, Van Thiel DH, Sanghvi A, Seltman H (1985) Biliary excretion of cyclosporine in liver transplant patients. Transpl Proc 17: 286–289
Von Willebrand E, Häyry P (1983) Cyclosporin A deposits in renal allografts. Lancet ii: 189–192
Yee GC, Kennedy MS, Storb RS, Thomas ED (1984) Pharmacokinetics of intravenous cyclosporin in bone marrow transplant patients: comparison of two assay methods. Transplantation 38: 511–513
Yee GC, Lennon TP, Gmur DG, Carlin J, Schaffer RL, Kennedy MS, Deeg HJ (1986) Clinical pharmacology of cyclosporine in patients undergoing bone marrow transplantation. Transpl Proc 18 (Suppl) 153–159
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sonneveld, P., Kokenberg, E., Sizoo, W. et al. Concentrations of ciclosporin in allogeneic bone marrow recipients. Blut 55, 467–472 (1987). https://doi.org/10.1007/BF00367465
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00367465